This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Thursday's Health Winners & Losers

Health indices remained essentially flat Thursday, even as regulatory approvals and earnings results bumped a few stocks into the green.

Making "Winners & Losers" on back-to-back days, Human Genome Sciences (HGSI) corrected some of the hit it took Wednesday after announcing that it will lower the higher, less-frequent dose of its hepatitis C drug Albuferon in late-stage studies because of pulmonary side effects.

Shares tumbled more than 40% on Wednesday on speculation that a safety flag for the 1200 mcg once-monthly dose may cast a shadow on the Food and Drug Administration's reception of the twice-monthly 900 mcg dose as well.

On Thursday, Robert W. Baird upgraded the stock to outperform from neutral and Bear Stearns upgraded the stock to outperform from peer perform, noting that although development risk for the drug has increased, the current view and stock price are too pessimistic. Shares recently rebounded 51 cents or 9%, to $6.14.

The stock is a component of the Nasdaq biotechnology index, which was down 0.7%, at 800.04.

Also on the rise, Italian company Gentium (GENT) said Thursday that a data safety monitoring board (DSMB) conducted a safety analysis of Defibrotide for severe veno-occlusive disease and found no safety concerns.

The company said the DSMB did ask it to clarify and supplement certain trial data to complete the remainder of the interim analysis. Gentium plans to release further results of the review when that is complete. Shares were up 98 cents, or 10.7%, at $10.13.

On the regulatory side, MiddleBrook Pharmaceuticals (MBRK) received approval from the FDA on Thursday for its anti-infective Moxatag to treat pharyngitis and tonsillitis secondary to strep throat. The drug is the first once-daily amoxicillin therapy approved in the U.S.

The company agreed to submit a completed study report and data set for the drug in pediatric patients less than 12 years old within the next five years as part of a postmarketing commitment in accordance with the Pediatric Research Equity Act.

Shares rose $1.75, or a whopping 140%, to $3.

In earnings, Gilead Sciences (GILD - Get Report) reported revenue at $1.09 billion, a 22% year-over-year hike. The company said Wednesday postclose that it earned $401.6 million, or 41 cents a share, compared to a loss of $1.66 billion, or $1.81 a share, a year ago due to charges associated with the acquisition of Myogen. On an adjusted basis, Gilead reported earning $401.6 million, or 44 cents a share, an increase of 7% over the year-ago quarter.

Analysts polled by Thomson Financial had been expecting adjusted earnings of 40 cents a share on revenue of $1.08 billion.

Shares were up 93 cents, or 2%, to $45.71 on Thursday.

Also, Becton Dickinson (BDX - Get Report) rose $2.56, or 3%, to $87.17 after beating estimates Thursday. The company earned $271.5 million, or $1.07 a share, on revenue of $1.7 billion for its first quarter of 2008, vs. $142.8 million, or 56 cents a share, in the year-ago quarter.

Analysts surveyed by Thomson Financial were looking for $1.03 a share on revenue of $1.65 billion.

Looking ahead, the company expects earnings per share from continuing operations to increase to a range of $4.26 to $4.34 for full-year 2008 -- an 11% to 13% increase compared to 2007 adjusted earnings.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ABI $22.98 1.01%
GENT $55.26 -0.88%
BDX $139.81 0.00%
GILD $89.44 0.00%
AAPL $93.99 0.00%


Chart of I:DJI
DOW 15,973.84 +313.66 2.00%
S&P 500 1,864.78 +35.70 1.95%
NASDAQ 4,337.5120 +70.6750 1.66%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs